Search
Iodohippuric acid
go.drugbank.com/drugs/DB15445InvestigationalIodohippuric acid is under investigation in clinical trial NCT02599844 (Impact of Pediatric Acute Renal Injury in Severe Sepsis in Young Adults).
Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household settingPhenylbutyric acid
go.drugbank.com/drugs/DB06819ApprovedInvestigationalPhenylbutyric acid is a fatty acid and a derivative of [butyric acid] naturally produced by colonic bacteria fermentation. … It demonstrates a number of cellular and biological effects, such as relieving inflammation and acting as a chemical chaperone.
Synonyms: 4-Phenyl-n-butyric acid, γ-Phenyl-n-butyric acidCategories: Ammonium Ion Binding ActivityGivinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigational[L50316,A263446] Givinostat was granted FDA approval in March 2024 for the treatment of patients ≥6 years of age with Duchenne muscular dystrophy (DMD). … In the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss.
Sucralfate
go.drugbank.com/drugs/DB00364ApprovedInvestigationalSucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers [FDA label], gastro-esophageal reflux disease (GERD), gastritis … It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form [L6073, L6076].
Synonyms: Hexadeca-μ-hydroxytetracosahydroxy[μ8-[1,3,4,6-tetra-O-sulfo-β-Dfructofuranosyl-α-D-glucopyranoside tetrakis(hydrogen sulfato)8-)]]hexadecaaluminumProducts: Nu-sucralfate - Tab 1gmNitisinone
go.drugbank.com/drugs/DB00348ApprovedNitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria.
Saprisartan
go.drugbank.com/drugs/DB01347ExperimentalSaprisartan is an AT1 receptor antagonist. It is based on medications of losartan's prototypical chemical structure. … The mode of (functional) AT1 receptor antagonism has been characterized as insurmountable/noncompetitive for saprisartan.
Categories: Agents Acting on the Renin-Angiotensin SystemPimecrolimus
go.drugbank.com/drugs/DB00337ApprovedInvestigationalIt is currently available as a topic cream used in the treatment of atopic dermatitis (eczema). … Pimecrolimus is an immunomodulating agent that was first marketed by Novartis under the trade name Elidel. It is now promoted in Canada by Galderma since early 2007.
Categories: Analgesics, Non-NarcoticMyocardial Infarction
go.drugbank.com/conditions/DBCOND0027900Drugs: Acetylsalicylic acid · Alirocumab · Atenolol · Atorvastatin · Bempedoic acid · Colchicine +13 moreBusulfan
go.drugbank.com/drugs/DB01008ApprovedInvestigationalBusulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.
Tozuleristide
go.drugbank.com/drugs/DB15375InvestigationalTozuleristide is under investigation in clinical trial NCT02464332 (Safety Study of BLZ-100 in Adult Subjects With Sarcoma Undergoing Surgery).
Categories: Diagnostic Uses of Chemicals, Compounds used in a research, industrial, or household setting